NCT01390064View on ClinicalTrials.gov

Vaccination of High Risk Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2019

Conditions
Stage IV Breast Cancer
Interventions
BIOLOGICAL

Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG

All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Arkansas

OTHER

NCT01390064 - Vaccination of High Risk Breast Cancer Patients | Biotech Hunter | Biotech Hunter